Market Conditions Increase Demand for Biotechnology and Pharmaceutical Partnerships

Apr 23, 2001, 01:00 ET from IBC USA Conferences

    WESTBOROUGH, Mass., April 23 /PRNewswire Interactive News Release/ -- More
 than ever before, biotechnology and pharmaceutical companies must form
 partnerships to stay ahead of their competition.  Finding the right partner at
 the right time is akin to finding a needle in a haystack.
     Successful partnerships occur when companies not only recognize a
 potential fit with another company, but also have been able to determine value
 while dealing with due diligence items such as legal, financial, patent and
 management.  The process takes time and money - and there is no guarantee for
 success.
     Multi-million dollar strategic alliances are revolutionizing the
 biotechnology and pharmaceutical industry.   Some of the industry's biggest
 players, such as CuraGen, Novartis and Eli Lilly have been able to partner
 successfully, but many potential partnerships have been doomed by the
 companies' inability to close the gap.
     The Novartis and Vertex collaboration is one of the largest drug discovery
 partnerships in history.   Details of the benefits, incentives and overall
 structure of the contract will be examined at the Drug Discovery Technology
 2001 event in Boston this August.
     "Alliances have been as central to the growth of the biotechnology
 industry as advances in the sciences.  Biotechnology and pharmaceutical
 companies are now structuring more innovative types of alliances that leverage
 scientific research as well as late stage pipeline and commercial
 opportunities," said Steven H. Holtzman, Chief Business Officer, Millennium
 Pharmaceuticals (Nasdaq: MLMN).
     Steven Holtzman is the keynote presenter for the one day summit on
 "Creative Partnering and Deal-Making in Drug Discovery" at the August Drug
 Discovery Technology conference.  This talk will review the partnering and
 alliance strategy Millennium has used to build its capabilities.
 Breakthrough features of the Aventis/ Millennium alliance will also be
 discussed.
     Strategic alliances, partnerships and licensing agreements are vital
 issues the biotechnology and pharmaceutical industry is facing today. Drug
 Discovery Technology 2001 has recognized the importance of partnering in this
 industry.  This event will provide case studies of the industry's major
 partnerships, and more importantly, the many issues and challenges in drug
 discovery deal-making.
     IBC USA Conferences is an independent organizer unaffiliated with any
 industrial or special interest organizations, that provides a neutral,
 unbiased forum for the evaluation of current research, market trends,
 technological developments and applications.
     IBC USA Conferences, Inc. is part of The Informa Group plc (LSE:   INF)
 which is quoted on the London Stock Exchange. The Informa Group has been
 serving the information needs of the international life sciences industry for
 over 20 years.
     IBC also organizes major international activities in mainland Europe,
 Central & Eastern Europe, the former Soviet Union, Central Asia, the Middle
 and Far East, North and South America and North and South Africa. IBC USA
 Conferences is headquartered in Westborough, Massachusetts.
     IBC's 6th Annual Drug Discovery Technology 2001 Conference and Exhibition
 will be held August 12-17, 2001 in Boston, MA.
 More information can be found online at: www.drugdisc.com
 
      Media Contact:
      Ellen Massa
      IBC USA Conferences, Boston, USA
      Telephone: (508) 616-5550 Ext. 213
      Facsimile: (508) 616-5533
      E-mail: emassa@ibcusa.com
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X88712468
 
 

SOURCE IBC USA Conferences
    WESTBOROUGH, Mass., April 23 /PRNewswire Interactive News Release/ -- More
 than ever before, biotechnology and pharmaceutical companies must form
 partnerships to stay ahead of their competition.  Finding the right partner at
 the right time is akin to finding a needle in a haystack.
     Successful partnerships occur when companies not only recognize a
 potential fit with another company, but also have been able to determine value
 while dealing with due diligence items such as legal, financial, patent and
 management.  The process takes time and money - and there is no guarantee for
 success.
     Multi-million dollar strategic alliances are revolutionizing the
 biotechnology and pharmaceutical industry.   Some of the industry's biggest
 players, such as CuraGen, Novartis and Eli Lilly have been able to partner
 successfully, but many potential partnerships have been doomed by the
 companies' inability to close the gap.
     The Novartis and Vertex collaboration is one of the largest drug discovery
 partnerships in history.   Details of the benefits, incentives and overall
 structure of the contract will be examined at the Drug Discovery Technology
 2001 event in Boston this August.
     "Alliances have been as central to the growth of the biotechnology
 industry as advances in the sciences.  Biotechnology and pharmaceutical
 companies are now structuring more innovative types of alliances that leverage
 scientific research as well as late stage pipeline and commercial
 opportunities," said Steven H. Holtzman, Chief Business Officer, Millennium
 Pharmaceuticals (Nasdaq: MLMN).
     Steven Holtzman is the keynote presenter for the one day summit on
 "Creative Partnering and Deal-Making in Drug Discovery" at the August Drug
 Discovery Technology conference.  This talk will review the partnering and
 alliance strategy Millennium has used to build its capabilities.
 Breakthrough features of the Aventis/ Millennium alliance will also be
 discussed.
     Strategic alliances, partnerships and licensing agreements are vital
 issues the biotechnology and pharmaceutical industry is facing today. Drug
 Discovery Technology 2001 has recognized the importance of partnering in this
 industry.  This event will provide case studies of the industry's major
 partnerships, and more importantly, the many issues and challenges in drug
 discovery deal-making.
     IBC USA Conferences is an independent organizer unaffiliated with any
 industrial or special interest organizations, that provides a neutral,
 unbiased forum for the evaluation of current research, market trends,
 technological developments and applications.
     IBC USA Conferences, Inc. is part of The Informa Group plc (LSE:   INF)
 which is quoted on the London Stock Exchange. The Informa Group has been
 serving the information needs of the international life sciences industry for
 over 20 years.
     IBC also organizes major international activities in mainland Europe,
 Central & Eastern Europe, the former Soviet Union, Central Asia, the Middle
 and Far East, North and South America and North and South Africa. IBC USA
 Conferences is headquartered in Westborough, Massachusetts.
     IBC's 6th Annual Drug Discovery Technology 2001 Conference and Exhibition
 will be held August 12-17, 2001 in Boston, MA.
 More information can be found online at: www.drugdisc.com
 
      Media Contact:
      Ellen Massa
      IBC USA Conferences, Boston, USA
      Telephone: (508) 616-5550 Ext. 213
      Facsimile: (508) 616-5533
      E-mail: emassa@ibcusa.com
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X88712468
 
 SOURCE IBC USA Conferences